Opra D Actions

• Actions of Opra D in details
• Opra D administration
• Opra D pharmacology
• Opra D reviews

Actions of Opra D in details

Pharmacology: Pharmacodynamics: Opra D is a selective peripheral dopamine antagonist at the D₂ dopamine receptors in the chemoreceptor trigger zone (CTZ) and stomach. It does not readily enter into the central nervous system (CNS) (the CTZ is considered to lie outside the blood brain barrier). It increases spontaneous gastric activity and antagonises dopamine inhibition of gastric emptying. Opra D has been shown to increase lower esophageal sphincter pressure and promotes esophageal and antral peristalsis and also increases pyloric dilation. It increases the frequency, amplitude and duration of duodenal contraction and reduces the small bowel transit time. Opra D has no acetylcholine-like effect.

Pharmacokinetics: Opra D is rapidly and almost completely (93%) absorbed after oral administration. Peak plasma concentrations occur within 30 min after oral administration. Opra D is strongly bound to plasma proteins (91-93%), lipoprotein binding being as important as albumin binding. Although tissue distribution studies are lacking in man, rat studies show widespread tissue distribution except to the CNS. Only small amounts of Opra D cross the placenta or reach breast milk.

Opra D undergoes extensive biotransformation with <1% excreted unchanged in urine. The effects of hepatic disease have not been documented; severe renal impairment may prolong the half-life (t_½) of Opra D. However, the contribution of renal clearance to total plasma clearance of Opra D is so small that accumulation of Opra D should not occur.

How should I take Opra D?

Dosing

The dose of Opra D will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of Opra D. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (tablets):
  • Treatment of gastrointestinal motility disorders:
    • Adults—10 milligrams (mg) three to four times daily. Some patients may require higher doses up to 20 mg three or four times daily.
  • Nausea and vomiting:
    • Adults—20 milligrams (mg) three to four times daily.

Missed Dose

If you miss a dose of Opra D, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Opra D administration

Should be taken on an empty stomach. Take 15-30 min before meals.

Opra D pharmacology

Gastrointestinal emptying (delayed) adjunct; peristaltic stimulant: The gastroprokinetic properties of Opra D are related to its peripheral dopamine receptor blocking properties. Opra D facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of Opra D are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level.

References

1. NCIt. "Domperidone: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
2. EPA DSStox. "Domperidone: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Opra D are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Opra D. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 6 here

Information checked by Dr. Sachin Kumar, MD Pharmacology